Reinvigorating CAR-T cells in solid tumors by targeting a family of proteins

Scientists at La Jolla Institute found that blocking Nr4a transcription factors could improve CAR-T cells' efficacy in solid tumors. (La Jolla Institute)

CAR-T cell therapies such as Gilead Sciences’ Yescarta and Novartis’ Kymriah have been proven useful against B-cell blood cancers, but the technology has been difficult to translate to solid tumors. Now scientists at the La Jolla Institute for Immunology have pinpointed proteins that contribute to that deficiency, a discovery that they believe could lead to better immuno-oncology therapies.

CAR-T treatments involve genetically engineering a patient’s own T cells to be able to mount an immune attack on cancer cells, and then infusing them back into the body. The immune system maintains a balance between immune response and immune tolerance, but that balance can tip toward the latter when T cells are exposed to chronic infection or the tumor microenvironment—a phenomenon known as "T cell exhaustion."  The exact molecular mechanism of T cell exhaustion has been a mystery,  but scientists believe it partially explains why CAR-Ts can't act on solid tumors.

Now the LJI researchers have found a way to rejuvenate exhausted T cells, and it involves a family of proteins called Nr4a transcription factors. When they gve CAR-Ts that lack all three Nr4a proteins to mice, their tumors began to shrink and they lived longer. The scientists reported their findings in the journal Nature.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The team, led by LJI researcher Anjana Rao, Ph.D., previously observed increased levels of Nr4a in T cells that fight chronic viral infections. Over time, those T cells seemed to grow tolerant to the viral antigens and stopped working. The Rao lab also found that another family of proteins called NFAT turned on Nr4a in T cells that entered tumors, suggesting that both proteins were somehow involved in wearing out cancer-fighting T cells.

Building on those findings, Rao and colleagues tested their theory in CAR-T cells. They modified some cells to lack the three Nr4a proteins. In tumor-bearing mouse models, the experimental CAR-T cells promoted tumor regression and kept most of the mice alive over the 90-day study period, while the rodents that got normal CAR-Ts died of cancer by day 35, according to the team. Moreover, the modified CAR-Ts showed greater anti-tumor activity than did similar cells that were only lacking one Nr4a protein.

RELATED: CAR-T 2.0? A split, universal and programmable system

CAR-T is still a relatively new class of cancer treatment, and scientists are working to improve upon the first generation of treatments. A team at Boston University recently created a split, universal and programmable CAR system that allows scientists to control the strength of T-cell activation to either avoid dangerous side effects or combat relapse. The team is working with Senti Biosciences on translating the technology into human studies.

Joyce Chen, the first author of the La Jolla study, says her team's research could open the door to addressing T-cell exhaustion in future CAR-T therapies. Identifying NFAT and Nr4a offers cancer researchers potential new targets for improving CAR-Ts, she says in a statement.

However, Chen admits there is much more work to be done. For example, the researchers need to understand the safety consequences of editing multiple genes in human cells. Chen says future research could investigate the role of other transcription factors in T cell exhaustion, especially those that are found along the NFAT and Nr4a signaling pathway.

Suggested Articles

Novocure’s tumor-treating electric field system scored an FDA nod in mesothelioma, making it the first new treatment in more than 15 years.

FLX Bio is renaming itself RAPT Therapeutics to reflect its expansion into allergy and inflammatory diseases.

The preclinical-stage biotech wants the cash to take an antisense oligonucleotide treatment for Dravet syndrome through to phase 3.